Skip to content
My WebMD Sign In, Sign Up
Zagam

Interactions

Fingolimod/Selected QT Prolongers

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

The first dose, and sometimes the second dose of fingolimod slows your heart rate. Some heart medications also slow down the heart rate, or may not be safe if your heart rate is too slow.

What might happen:

Your heart rate may go too low, or may become irregular.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together. Your doctor may want to change or discontinue one of your medications.If these medications are used together, doctor will closely monitor you in a medical facility for at least 6 to 24 hours after your first dose of fingolimod to be sure you are safe. Let your doctor know right away if you notice an irregular heartbeat (palpitations) or have any dizziness, fainting episodes, fatigue or chest pain.Do not start, stop, or change the dosage of any medicine before checking with them first.

References:

1.Gilenya (fingolimod) US prescribing information. Novartis Pharmaceuticals Corporation May, 2012.

2.Gilenya (fingolimod) Health Canada prescribing information. Novartis Pharmaceuticals September 23, 2011.

3.MHRA United Kingdom. Fingolimod (Gilenya): transient bradycardias and heart block after first dose - strengthened cardiovascular monitoring. Drug Safety Update Feb 2012;5(7):A1.

4.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, expect as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

More about Drugs and Medications

URAC: Accredited Health Web Site HONcode Seal AdChoices